QUOIN PHARMACEUTICALS, LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6901 USD | +0.73% |
|
+4.56% | -85.93% |
| 03-15 | Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating | MT |
| 03-14 | Quoin Pharmaceuticals Seeks M&A Opportunities | CI |
| Sales 2024 * | - | Sales 2025 * | 15.58M 1.25B | Capitalization | 2.53M 202M |
|---|---|---|---|---|---|
| Net income 2024 * | -9M -720M | Net income 2025 * | -9M -720M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.16 x |
| P/E ratio 2024 * |
-0.32
x | P/E ratio 2025 * |
-0.55
x | Employees | 4 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 26.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on Quoin Pharmaceuticals, Ltd.
More recommendations
More press releases
| 1 day | +1.88% | ||
| 1 week | +4.56% | ||
| Current month | -27.36% | ||
| 1 month | -26.59% | ||
| 3 months | -81.64% | ||
| 6 months | -83.72% | ||
| Current year | -85.93% |
1 week
0.60
0.75
1 month
0.600.98
Current year
0.606.18
1 year
0.6012.00
3 years
0.602 018.25
5 years
0.602 018.25
10 years
0.602 018.25
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Myers
CEO | Chief Executive Officer | 62 | 04/03/18 |
Denise Carter
FOU | Founder | 55 | 04/03/18 |
Gordon Dunn
DFI | Director of Finance/CFO | 60 | 31/10/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Sember
BRD | Director/Board Member | - | 27/10/21 |
Dennis Langer
BRD | Director/Board Member | 73 | 27/10/21 |
Joseph Cooper
BRD | Director/Board Member | 66 | 27/10/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 0.6901 | +0.73% | 27 478 |
| 29/04/24 | 0.6851 | +7.47% | 161,352 |
| 26/04/24 | 0.6375 | +1.19% | 56,890 |
| 25/04/24 | 0.63 | -0.33% | 242,254 |
| 24/04/24 | 0.6321 | -4.23% | 55,115 |
Delayed Quote Nasdaq, April 30, 2024 at 07:49 pm
More quotes
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Companyâs first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Calendar
05/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.6851
USD
Average target price
5.8
USD
Spread / Average Target
+746.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -85.93% | 2.53M | |
| +0.40% | 42.86B | |
| +11.89% | 42.74B | |
| +44.30% | 41.36B | |
| -6.20% | 27.68B | |
| +5.48% | 25.15B | |
| -24.08% | 18.63B | |
| +27.61% | 12.37B | |
| -3.78% | 11.92B | |
| +7.26% | 11.21B |
- Stock Market
- Equities
- QNRX Stock
